Here are the 8-K filings from Braveheart Bio, Inc. (BRVE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow BRVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRVE filings page.
Braveheart Bio, Inc. (BRVE) and Hengrui Pharma reported 52-week open-label extension results for investigational HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy. All 42 patients resumed treatment after the 12-week core study and washout. At Week 52, peak oxygen uptake rose a mean 2.7 mL/kg/min and KCCQ Clinical Summary Score rose 17.3 points from OLE baseline; 79% (33/42) had a Valsalva LVOT gradient below 30 mmHg.
57% (24/42) ended the study on the 40 mg twice-daily starting dose, and 90% reached the gradient threshold at one or more treatment visits. No on-treatment severe or serious adverse events were reported; two patients had transient site-measured LVEF reductions below 50% and resumed at a lower dose. A separate post hoc analysis of 84 non-obstructive HCM patients reported improvements across diastolic-function indices after 12 weeks. A fixed-dose Phase 2b oHCM study, TRUEHEART-HCM, was planned.
Braveheart Bio, Inc. (BRVE) reported unaudited results for the quarter ended June 30, 2026 and outlined progress on its lead cardiac myosin inhibitor BHB-1893. The company ended the quarter with $122.8 million in cash and cash equivalents, which, together with $404.5 million in net IPO proceeds received in August, would have brought cash to about $527.3 million on an as-adjusted basis. Management estimates this cash runway will fund operations into 2029.
R&D expenses rose to $11.1 million from virtually zero a year earlier, and G&A expenses increased to $4.8 million, leading to a quarterly net loss of $15.0 million and net loss attributable to common stockholders of $18.6 million, or $2.51 per share. The company has initiated the global Phase 3 LIONHEART-HCM trial in obstructive HCM and plans to start the NOBLEHEART-HCM Phase 3 trial in non-obstructive HCM in the first half of 2027, following encouraging Phase 2 data in both settings.
Braveheart Bio, Inc. updated its governing documents in connection with completing its initial public offering. The company filed a Second Amended and Restated Certificate of Incorporation effective immediately prior to the IPO, authorizing 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. The new charter removes references to prior preferred series and eliminates stockholder ability to act by written consent or to call special meetings, shifting those powers to formal meeting processes.
The company’s Second Amended and Restated Bylaws, effective upon the Form S-1 registration statement’s effectiveness, establish procedures for stockholder actions at meetings, introduce an advance notice process for stockholder proposals and director nominations, and align bylaw provisions with the updated charter.